Insights

  • Date

  • Content Type

  • Reset

Blog

Getting the balance right with biosimilars

16.05.22

By Peter Lavrencic

As many of the top-selling biotech drugs face loss of patent in the next few years, a large number...

Blog

A Meeting of Minds: Cell & Gene Conference Brings Tight-Knit Community Together

16.05.22

By Emma Cheesman-Ungstrup | Liron Sarid-Krebs | Elena Meurer

After two years stuck at home and only able to attend virtual conferences, the 2022 Cell & Gene Meeting...

Blog

The dos and don’ts of scientific due diligence

12.04.22

By Dr. Diane Seimetz

Partnering, mergers and acquisitions, and product licensing require careful preparation, particularly when it comes to

Blog

The Risk-Reward Conundrum

30.03.22

By Dr. Diane Seimetz

Opportunities and challenges of bringing innovative therapies to market.

Blog

Rare Disease Day: marking 2 decades of advancement in orphan treatments

28.02.22

By Christian Schneider

While every day can be a challenge for those living with rare and debilitating conditions, Rare Disease Day...

Blog

Happily ever after: Why scientific due diligence is key to a successful M&A marriage

23.02.22

By Dr. Diane Seimetz

Why scientific due diligence is key to a successful M&A